Clinical Trial Update: Camrelizumab With Apatinib as Neoadjuvant Therapy for Participants With Resectable Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update investigating camrelizumab with apatinib as neoadjuvant therapy for resectable non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Apatinib (apatinib)
• Camrelizumab (camrelizumab)

Snippet

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Conditions: NSCLC | Phase 2 | Status: UNKNOWN